Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study

被引:6
|
作者
Park, Joo-Hyun [1 ]
Song, Yun-Mi [2 ]
Jung, Jin-Hyung [3 ]
Han, Kyungdo [4 ]
机构
[1] Korea Univ, Coll Med, Dept Family Med, Ansan Hosp, Ansan, South Korea
[2] Sungkyunkwan Univ, Samsung Med Ctr, Dept Family Med, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea
[3] Catholic Univ, Dept Biostat, Coll Med, Seoul, South Korea
[4] Soongsil Univ, Dept Stat & Actuarial Sci, Seoul, South Korea
关键词
Fractures; Gastroesophageal reflux; Histamine-2 receptor antagonist; Osteoporosis; Proton pump inhibitor; BONE-MINERAL DENSITY; HIP FRACTURE; VITAMIN-B-12; OMEPRAZOLE; MEDICATIONS; ABSORPTION; SECRETION; INCREASE; HEALTH; DRUGS;
D O I
10.1016/j.bone.2020.115306
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The influence of proton pump inhibitors (PPIs) on the risk of osteoporotic fractures remains to be elucidated, especially in the Asian population. This study evaluated the risk of osteoporotic fractures in elderly female Korean PPI users compared to histamine-2 receptor antagonist (H2RA) users, as well as the relationship between fractures and the duration, dose, and pattern of use of PPI. We screened a nationwide cohort of elderly Korean women who underwent bone mineral density measurements during their 66-year-old life-transition medical examination between 2009 and 2014. Study subjects included 8903 cases diagnosed with new osteoporotic fractures and 44,515 matched controls (1:5 ratio based on cohort entry date, follow-up duration, and baseline osteoporosis status) without fractures. They were followed up until 2015. Information on the exposure to PPI or H2RA, occurrence of fracture, and covariates were obtained from the Korean National Health Insurance Service data. Covariate-adjusted odds ratio (aOR) and 95% confidence interval (CI) were estimated using conditional logistic regression analysis. PPI use was associated with an increased risk of osteoporotic fractures (aOR: 1.13, 95% CI: 1.07, 1.18) compared with H2RA-only use. Increasing duration of PPI use was positively associated with the risk of osteoporotic fracture [aOR (95% CI) of long-term PPI use (>= 1 year): 1.3 (1.09, 1.56)]. Recent PPI use within the last year was associated with an increased risk of fracture (aOR: 1.31, 95% CI: 1.23, 1.38), whereas remote PPI use was not (aOR: 0.98, 95% CI: 0.92, 1.04). The risk of fracture did not increase with the increasing cumulative PPI dose. Compared with the use of H2RA alone, PPI use was associated with an increased risk of osteoporotic fractures in elderly Korean women, particularly among those who had used PPI within the last year or for more than one year.
引用
收藏
页数:9
相关论文
共 45 条
  • [21] Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis
    C.-H. Chen
    C.-L. Lin
    C.-H. Kao
    Osteoporosis International, 2016, 27 : 2117 - 2126
  • [22] Risk of Infertility in Males with Obstructive Sleep Apnea: A Nationwide, Population-Based, Nested Case-Control Study
    Lin, Pin-Yao
    Ting, Hua
    Lu, Yen-Ting
    Huang, Jing-Yang
    Lee, Tsung-Hsien
    Lee, Maw-Sheng
    Wei, James Cheng-Chung
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (06):
  • [23] A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate
    Joongyub Lee
    KyungEun Youn
    Nam-Kyong Choi
    Jin-Ho Lee
    DongYoon Kang
    Hong-Ji Song
    Byung-Joo Park
    Journal of Gastroenterology, 2013, 48 : 1016 - 1022
  • [24] Association Between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study
    Peng, Yen-Chun
    Lin, Cheng-Li
    Yeh, Hong-Zen
    Chang, Chi-Sen
    Wu, Yu-Lin
    Kao, Chia-Hung
    MEDICINE, 2016, 95 (15)
  • [25] Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy
    Kirchmayer, Ursula
    Sorge, Chiara
    Sultana, Janet
    Lapi, Francesco
    Onder, Graziano
    Agabiti, Nera
    Cascini, Silvia
    Roberto, Giuseppe
    Corrao, Giovanni
    Vitale, Cristiana
    Lucenteforte, Ersilia
    Mugelli, Alessandro
    Davoli, Marina
    Bartolini, C.
    Bernabei, R.
    Bettiol, A.
    Bonassi, S.
    Caputi, A. P.
    Chinellato, A.
    Fini, M.
    Gini, R.
    Giorgianni, F.
    Lombardi, N.
    Rea, F.
    Tari, M.
    Trifiro, G.
    Vannacci, A.
    Vetrano, D. L.
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2019, 10 : 1 - 14
  • [26] Chronic Proton-Pump Inhibitor Therapy and Fracture Risk in Women Aged Between 50 and 65 years: A Retrospective Case-Control Study
    Patel, Nimesh
    Fayed, Mohamed
    Faldu, Priyansh
    Maroun, Wissam
    Chandarana, Janki
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [27] Risk of Cervical Abnormalities in Women With Inflammatory Bowel Disease: A Population-Based Nested Case-Control Study
    Singh, Harminder
    Demers, Alain A.
    Nugent, Zoann
    Mahmud, Salaheddin M.
    Kliewer, Erich V.
    Bernstein, Charles N.
    GASTROENTEROLOGY, 2009, 136 (02) : 451 - 458
  • [28] Association between Proton Pump Inhibitor Use and the Risk of Female Cancers: A Nested Case-Control Study of 23 Million Individuals
    Nhi Thi Hong Nguyen
    Huang, Chih-Wei
    Wang, Ching-Huan
    Lin, Ming-Chin
    Hsu, Jason C.
    Hsu, Min-Huei
    Iqbal, Usman
    Nguyen, Phung-Anh
    Yang, Hsuan-Chia
    CANCERS, 2022, 14 (24)
  • [29] Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease-a nested case-control study
    Torvinen-Kiiskinen, S.
    Tolppanen, A. -M.
    Koponen, M.
    Tanskanen, A.
    Tiihonen, J.
    Hartikainen, S.
    Taipale, H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (08) : 1135 - 1142
  • [30] Is use of a long-term proton pump inhibitor or histamine-2 receptor antagonist a risk factor for iron-deficiency anaemia in Taiwan? A neglected clinical drug-drug interaction
    Wu, Yi-Ting
    Lu, Ya-Ting
    Chu, Chao-Yu
    Chao, Horng-Jiun
    Kuo, Li-Na
    Cheng, Kuei-Ju
    Chen, Hsiang-Yin
    FAMILY PRACTICE, 2023,